Altimmune Inc at Barclays Global Healthcare Conference Transcript
Hi, Good morning, everyone. I'm Ellie Merle, one of the biotech analysts here at Barclays. Very happy to have Altimmune here with us for a fireside chat. Joining us from Altimmune, we have Jerry Durso, Chief Executive Officer; Christophe Arbet-Engels, sorry if I butchered your name, Chief Medical Officer; and Greg Weaver, Chief Financial Officer. Thank you all so much for joining us.
Happy to be here.
To begin, maybe if we can start with a brief overview of the key highlights of Altimmune's progress over 2025 and into the first quarter of '26, including on the financial front as well.
Sure. So we've been busy as a company and a lot going on and really an exciting year ahead of us in 2026. Last year, significant progress on the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
